These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 22373240)
1. Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. Magbanua MJ; Sosa EV; Scott JH; Simko J; Collins C; Pinkel D; Ryan CJ; Park JW BMC Cancer; 2012 Feb; 12():78. PubMed ID: 22373240 [TBL] [Abstract][Full Text] [Related]
2. Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Magbanua MJ; Sosa EV; Roy R; Eisenbud LE; Scott JH; Olshen A; Pinkel D; Rugo HS; Park JW Cancer Res; 2013 Jan; 73(1):30-40. PubMed ID: 23135909 [TBL] [Abstract][Full Text] [Related]
3. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Shaffer DR; Leversha MA; Danila DC; Lin O; Gonzalez-Espinoza R; Gu B; Anand A; Smith K; Maslak P; Doyle GV; Terstappen LW; Lilja H; Heller G; Fleisher M; Scher HI Clin Cancer Res; 2007 Apr; 13(7):2023-9. PubMed ID: 17404082 [TBL] [Abstract][Full Text] [Related]
4. Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer. Gupta S; Li J; Kemeny G; Bitting RL; Beaver J; Somarelli JA; Ware KE; Gregory S; Armstrong AJ Clin Cancer Res; 2017 Mar; 23(5):1346-1357. PubMed ID: 27601596 [No Abstract] [Full Text] [Related]
5. Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer. Reyes EE; VanderWeele DJ; Isikbay M; Duggan R; Campanile A; Stadler WM; Vander Griend DJ; Szmulewitz RZ J Transl Med; 2014 Nov; 12():313. PubMed ID: 25424879 [TBL] [Abstract][Full Text] [Related]
6. Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance). Magbanua MJM; Rugo HS; Wolf DM; Hauranieh L; Roy R; Pendyala P; Sosa EV; Scott JH; Lee JS; Pitcher B; Hyslop T; Barry WT; Isakoff SJ; Dickler M; Van't Veer L; Park JW Clin Cancer Res; 2018 Mar; 24(6):1486-1499. PubMed ID: 29311117 [No Abstract] [Full Text] [Related]
7. Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis. Greene SB; Dago AE; Leitz LJ; Wang Y; Lee J; Werner SL; Gendreau S; Patel P; Jia S; Zhang L; Tucker EK; Malchiodi M; Graf RP; Dittamore R; Marrinucci D; Landers M PLoS One; 2016; 11(11):e0165089. PubMed ID: 27851748 [TBL] [Abstract][Full Text] [Related]
8. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Attard G; Swennenhuis JF; Olmos D; Reid AH; Vickers E; A'Hern R; Levink R; Coumans F; Moreira J; Riisnaes R; Oommen NB; Hawche G; Jameson C; Thompson E; Sipkema R; Carden CP; Parker C; Dearnaley D; Kaye SB; Cooper CS; Molina A; Cox ME; Terstappen LW; de Bono JS Cancer Res; 2009 Apr; 69(7):2912-8. PubMed ID: 19339269 [TBL] [Abstract][Full Text] [Related]
9. Isolation of circulating tumor cells by immunomagnetic enrichment and fluorescence-activated cell sorting (IE/FACS) for molecular profiling. Magbanua MJ; Park JW Methods; 2013 Dec; 64(2):114-8. PubMed ID: 23896286 [TBL] [Abstract][Full Text] [Related]
10. A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients. García JL; Lozano R; Misiewicz-Krzeminska I; Fernández-Mateos J; Krzeminski P; Alfonso S; Marcos RA; García R; Gómez-Veiga F; Virseda Á; Herrero M; Olmos D; Cruz-Hernández JJ Clin Transl Oncol; 2017 Nov; 19(11):1350-1357. PubMed ID: 28600675 [TBL] [Abstract][Full Text] [Related]
11. Molecular profiling of tumor cells in cerebrospinal fluid and matched primary tumors from metastatic breast cancer patients with leptomeningeal carcinomatosis. Magbanua MJ; Melisko M; Roy R; Sosa EV; Hauranieh L; Kablanian A; Eisenbud LE; Ryazantsev A; Au A; Scott JH; Park JW Cancer Res; 2013 Dec; 73(23):7134-43. PubMed ID: 24142343 [TBL] [Abstract][Full Text] [Related]
12. Genomic high-resolution profiling of single CKpos/CD45neg flow-sorting purified circulating tumor cells from patients with metastatic breast cancer. Neves RP; Raba K; Schmidt O; Honisch E; Meier-Stiegen F; Behrens B; Möhlendick B; Fehm T; Neubauer H; Klein CA; Polzer B; Sproll C; Fischer JC; Niederacher D; Stoecklein NH Clin Chem; 2014 Oct; 60(10):1290-7. PubMed ID: 25267515 [TBL] [Abstract][Full Text] [Related]
13. Androgen receptor nuclear localization correlates with AR-V7 mRNA expression in circulating tumor cells (CTCs) from metastatic castration resistance prostate cancer patients. Worroll D; Galletti G; Gjyrezi A; Nanus DM; Tagawa ST; Giannakakou P Phys Biol; 2019 Mar; 16(3):036003. PubMed ID: 30763921 [TBL] [Abstract][Full Text] [Related]
14. Androgen receptor expression on circulating tumor cells in metastatic breast cancer. Fujii T; Reuben JM; Huo L; Espinosa Fernandez JR; Gong Y; Krupa R; Suraneni MV; Graf RP; Lee J; Greene S; Rodriguez A; Dugan L; Louw J; Lim B; Barcenas CH; Marx AN; Tripathy D; Wang Y; Landers M; Dittamore R; Ueno NT PLoS One; 2017; 12(9):e0185231. PubMed ID: 28957377 [TBL] [Abstract][Full Text] [Related]
15. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Leversha MA; Han J; Asgari Z; Danila DC; Lin O; Gonzalez-Espinoza R; Anand A; Lilja H; Heller G; Fleisher M; Scher HI Clin Cancer Res; 2009 Mar; 15(6):2091-7. PubMed ID: 19276271 [TBL] [Abstract][Full Text] [Related]
16. Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells. Dago AE; Stepansky A; Carlsson A; Luttgen M; Kendall J; Baslan T; Kolatkar A; Wigler M; Bethel K; Gross ME; Hicks J; Kuhn P PLoS One; 2014; 9(8):e101777. PubMed ID: 25084170 [TBL] [Abstract][Full Text] [Related]
17. An Accessible and Unique Insight into Metastasis Mutational Content Through Whole-exome Sequencing of Circulating Tumor Cells in Metastatic Prostate Cancer. Faugeroux V; Lefebvre C; Pailler E; Pierron V; Marcaillou C; Tourlet S; Billiot F; Dogan S; Oulhen M; Vielh P; Rameau P; NgoCamus M; Massard C; Laplace-Builhé C; Tibbe A; Taylor M; Soria JC; Fizazi K; Loriot Y; Julien S; Farace F Eur Urol Oncol; 2020 Aug; 3(4):498-508. PubMed ID: 31412010 [TBL] [Abstract][Full Text] [Related]
18. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Friedlander TW; Roy R; Tomlins SA; Ngo VT; Kobayashi Y; Azameera A; Rubin MA; Pienta KJ; Chinnaiyan A; Ittmann MM; Ryan CJ; Paris PL Cancer Res; 2012 Feb; 72(3):616-25. PubMed ID: 22158653 [TBL] [Abstract][Full Text] [Related]
19. Multigene model for predicting metastatic prostate cancer using circulating tumor cells by microfluidic magnetophoresis. Cho H; Chung JI; Kim J; Seo WI; Lee CH; Morgan TM; Byun SS; Chung JS; Han KH Cancer Sci; 2021 Feb; 112(2):859-870. PubMed ID: 33232539 [TBL] [Abstract][Full Text] [Related]
20. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Jiang Y; Palma JF; Agus DB; Wang Y; Gross ME Clin Chem; 2010 Sep; 56(9):1492-5. PubMed ID: 20581083 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]